Older adults · California
Studies for adults 50 and older in California
These studies set a minimum age of 50 or older in their official record. Many look at conditions more common with age, and some vaccine and memory studies specifically need older participants.
117 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Irvine, CA + 17 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Adverum Biotechnologies, Inc.
- Location
- Bakersfield, CA + 78 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
Regenerative Patch Technologies, LLC
- Location
- Huntington Beach, CA + 4 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Anaheim, CA + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 1/Phase 2
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
AbbVie
- Location
- Irvine, CA + 10 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 2
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
ONL Therapeutics
- Location
- Bakersfield, CA + 55 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 3
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Dompé Farmaceutici S.p.A
- Location
- Los Angeles, CA + 13 other US sites
- Eligibility basics
- Ages 50–80
- RecruitingPhase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Astellas Institute for Regenerative Medicine
- Location
- Los Angeles, CA + 12 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
ADARx Pharmaceuticals, Inc.
- Location
- Bakersfield, CA + 18 other US sites
- Eligibility basics
- Ages 60+
- Recruiting
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
i-Lumen Scientific AUS PTY LTD
- Location
- Poway, CA + 5 other US sites
- Eligibility basics
- Ages 60+
- Recruiting
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
MMI (Medical Microinstruments, Inc.)
- Location
- Palo Alto, CA + 2 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 1/Phase 2
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
4D Molecular Therapeutics
- Location
- Oxnard, CA + 19 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Amgen
- Location
- Beverly Hills, CA + 193 other US sites
- Eligibility basics
- Ages 50–105
- RecruitingPhase 3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Orange, CA + 7 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2/Phase 3
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Exciva GmbH
- Location
- Murrieta, CA + 6 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2/Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
EyeBiotech Ltd.
- Location
- Encino, CA + 51 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
Adverum Biotechnologies, Inc.
- Location
- Bakersfield, CA + 11 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Anthos Therapeutics, Inc.
- Location
- Huntington Beach, CA + 131 other US sites
- Eligibility basics
- Ages 65+
- RecruitingPhase 1/Phase 2
Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)
EicOsis Human Health Inc.
- Location
- Sacramento, CA
- Eligibility basics
- Ages 50–80
- RecruitingPhase 3
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Eli Lilly and Company
- Location
- Huntington Beach, CA + 41 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2/Phase 3
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
Kardigan, Inc.
- Location
- Beverly Hills, CA + 46 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or…
Ocular Therapeutix, Inc.
- Location
- Bakersfield, CA + 7 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Bristol-Myers Squibb
- Location
- Chino, CA + 2 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 1
A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
GlaxoSmithKline
- Location
- Fair Oaks, CA + 11 other US sites
- Eligibility basics
- Ages 65–85